We note that in this study, we use the term “preclinical” to identify those who are likely to receive clinical diagnosis of Alzheimer’s Disease in the future, not necessarily based on the amyloid deposition, pathological tau, and neurodegeneration (ATN) biomarker-based framework presented in Jack et al. 8 Specifically, we are interested in identifying those who are currently clinically normal but are on the trajectory to develop MCI in the near future. The gene discussed is MAPT; the disease is Alzheimer disease.